Cardioprotection by orotic acid: Metabolism and mechanism of action

被引:21
|
作者
Richards, SM
Conyers, RAJ
Fisher, JL
Rosenfeldt, FL [1 ]
机构
[1] Baker Med Res Inst, POB 348, Prahran, Vic 3181, Australia
[2] Alfred Hosp, Dept Pathol, Prahran, Vic 3181, Australia
关键词
purines; myocardial ischemia; infarction; orotic acid;
D O I
10.1006/jmcc.1997.0550
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The pyrimidine base, erotic acid (OA), improves the function of recently infarcted hearts subjected to global ischemia but its mechanism of action is unclear, Our aims were to examine (i) in normal rats, the effect of OA on pyrimidine levels in plasma, liver and heart; (ii) in rats with normal or infarcted hearts, the effect of OA on adenine nucleotide metabolism and mechanical function, before and after global ischemia, To investigate the metabolism of OA, normal rats received 100 mg/kg OA, and changes in plasma and tissue concentrations of pyrimidines were examined. The effects of OA were also studied in rats receiving OA for 2 days after corollary ligation or sham operations, and plasma and tissue pyrimidine concentrations examined, Their hearts were isolated and perfused, then subjected to 30 min of global ischemia. Mechanical function and adenine nucleotide content were assessed pre-and post-ischemia. In normal, unoperated rats, administration of 100 mgikg OA significantly increased hepatic uracil and cytosine nucleotide concentrations, then increased plasma uridine (+/-124%) and cytidine (+55%), and transiently increased myocardial uracil nucleotides (+21%). Infarction significantly reduced recovery of cardiac work after global ischemia (sham=62%; infarct=26%; P<0.05), and OA treatment in infarcted hearts increased post-ischemic work by 192% (P<0.05), but not in shams. Pre-ischemic ATE was reduced in the surviving myocardium of infarcted hearts from 21.7+/-0.8 to 14.7+/-0.71 mu mol/g dry weight (P<0.001) and total adenine nucleotides (TAN) from 30.3 +/- 0.8 to 22.4 +/- 1.1 mu mol/g dry weight (P<0.001). OA treatment prevented these reductions in infarcted hearts (ATE 20.7 +/- 0.5; TAN, 29.1 +/- 0.6 mu mol/g dry weight). We conclude that OA protects the infarcted heart against global ischemia by enhancing hepatic release of pyrimidine nucleosides into the plasma, which then prevent depletion of adenine nucleotides in the survivingmyocardium. (C) 1997 Academic Press Limited.
引用
收藏
页码:3239 / 3250
页数:12
相关论文
共 50 条
  • [1] LIPOTROPIC ACTION OF OROTIC ACID
    PORTA, EA
    MANNING, C
    HARTROFT, WS
    GASTROENTEROLOGY, 1968, 54 (01) : 164 - &
  • [2] LIPOTROPIC ACTION OF OROTIC ACID
    PORTA, EA
    MANNING, C
    HARTROFT, WS
    ARCHIVES OF PATHOLOGY, 1968, 86 (02): : 217 - &
  • [3] OROTIC-ACID, A SERUM BILIRUBIN LOWERING COMPOUND - SUGGESTED MECHANISM OF ACTION
    COHEN, MI
    MCNAMARA, H
    PEDIATRIC RESEARCH, 1973, 7 (04) : 319 - 319
  • [4] A SURVEY OF THE METABOLISM OF OROTIC ACID IN THE RAT
    HURLBERT, RB
    POTTER, VR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1952, 195 (01) : 257 - 270
  • [5] Orotic acid excretion and arginine metabolism
    Brosnan, Margaret E.
    Brosnan, John T.
    JOURNAL OF NUTRITION, 2007, 137 (06): : 1656S - 1661S
  • [6] STUDIES ON CONGENITAL OROTIC ACIDURIA - COMPARISON OF OROTIC ACID METABOLISM IN MICROORGANISMS
    SMITH, LH
    LOTZ, M
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1963, 61 (02): : 211 - &
  • [7] Mechanism of cardioprotective effect of orotic acid
    Rosenfeldt, FL
    Richards, SM
    Lin, Z
    Pepe, S
    Conyers, RAJ
    CARDIOVASCULAR DRUGS AND THERAPY, 1998, 12 (Suppl 2) : 159 - 170
  • [8] Mechanism of Cardioprotective Effect of Orotic Acid
    Franklin L. Rosenfeldt
    Stephen M. Richards
    Zaw Lin
    Salvatore Pepe
    Robert A.J. Conyers
    Cardiovascular Drugs and Therapy, 1998, 12 : 159 - 170
  • [9] Retinoic acid metabolism and mechanism of action: A review
    Marill, J
    Idres, N
    Capron, CC
    Nguyen, E
    Chabot, GG
    CURRENT DRUG METABOLISM, 2003, 4 (01) : 1 - 10
  • [10] PYRIMIDINE METABOLISM IN MAN - BIOSYNTHESIS OF OROTIC ACID
    SMITH, LH
    BAKER, F
    JOURNAL OF CLINICAL INVESTIGATION, 1958, 37 (06): : 932 - 933